NFlection Therapeutics is a Cambridge, Massachusetts based biotechnology company focused on the discovery and development of effective therapies for genetic disorders including cutaneous neurofibromas in Neurofibromatosis 1, congenital birthmarks, including nevus sebaceous and epidermal nevi, as well as other RASopathies with high unmet need.  We are funded by venBio and F-Prime Capital, and have assembled a high caliber team of experienced industry professionals and key opinion leaders to develop NFX-179, a “soft” topical MEK inhibitor for these disfiguring RASopathies of the skin that mainly have surgical options available. With the help of patients and physicians, we aim to bring patients a safe and effective non-surgical treatment for cutaneous neurofibromas, epidermal nevi, and nevus sebaceous.

logo 4png.png